Proficio Capital Partners LLC bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 12,528 shares of the biotechnology company's stock, valued at approximately $1,725,000.
Other institutional investors also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB acquired a new stake in Ascendis Pharma A/S in the third quarter valued at approximately $30,000. Blue Trust Inc. boosted its stake in Ascendis Pharma A/S by 415.2% in the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 328 shares in the last quarter. Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S in the third quarter valued at approximately $60,000. GAMMA Investing LLC boosted its stake in Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 214 shares in the last quarter. Finally, Sanctuary Advisors LLC acquired a new stake in Ascendis Pharma A/S in the fourth quarter valued at approximately $203,000.
Ascendis Pharma A/S Stock Performance
Shares of Ascendis Pharma A/S stock traded down $5.77 during trading on Friday, hitting $145.74. 350,979 shares of the company's stock were exchanged, compared to its average volume of 453,054. The business has a 50-day simple moving average of $137.32 and a 200-day simple moving average of $134.39. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $158.00. The stock has a market capitalization of $8.84 billion, a price-to-earnings ratio of -20.53 and a beta of 0.62.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.64. On average, equities analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several brokerages have weighed in on ASND. Morgan Stanley set a $180.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday, February 18th. TD Cowen decreased their price target on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a report on Friday, November 15th. StockNews.com raised shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Cantor Fitzgerald raised their price target on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, February 25th. Finally, JPMorgan Chase & Co. raised their price target on shares of Ascendis Pharma A/S from $167.00 to $168.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $202.36.
Get Our Latest Stock Report on ASND
About Ascendis Pharma A/S
(
Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Featured Stories
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
